Pharmaceutical Technology's In the Lab eNewsletter
The companies will merge to offer a broader range of analytical data packages and regulatory support for biopharmaceuticals.
On April 10, 2019, Protagen Protein Services (PPS), a German contract research organization (CRO) specializing in protein analytics, and BioAnalytix, a Cambridge, MA-based provider of biologic development analytical services, announced that the companies will merge into one global CRO.
Under the conditions of the merger, PPS and BioAnalytix will combine their respective analytical platforms, programs, and teams based in the United States and Europe to design, generate, and deliver integrated analytical data packages and scientific, technical, and regulatory support for all stages of biopharmaceutical development, including biosimilars. Services include developability and lead optimization, clone selection and process development, extended characterization and comparability, stability testing for control strategy design and chemistry, manufacturing, and control filings through commercialization, and full GMP testing of commercial products.
“Both companies have shared a similar vision, entrepreneurial agility, and heritage of excellence in supporting leading pharmaceutical companies with high-end analytics and strategic solutions through development,” said Martin Blüggel, founder and CEO of Protagen Protein Services, in a company press release. “We are fascinated to serve our pharma partners more directly in the FDA and EMEA territories and continue our expansion in capacities and capabilities now including BioAnalytix’s innovative areas such as [hydrogen deuterium exchange–mass spectrometry] and in-vivo [critical quality attribute] mapping.”
“The broader platforms will enable us to provide a significantly greater range of analytic data packages and regulatory support here in the US as we strengthen our focus on delivering analytic excellence in advancing, de-risking and accelerating all stages of biotherapeutic development with our pharma partners,” said Kirtland Poss, Founder and CEO of BioAnalytix, in the release.
Source: Protagen Protein Services
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.